Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma (Q33377828)

26 July 2017

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma (English)

1 reference

26 July 2017

1 reference

1 reference

2

Barbara Pro

0 references

Luis E. Fayad

series ordinal

3

object named as

Luis E Fayad

0 references

Sattva S Neelapu

series ordinal

7

object named as

Sattva Neelapu

1 reference

PubMed ID

18085611

26 July 2017

Fredrick B Hagemeister

series ordinal

6

object named as

Fredrick Hagemeister

1 reference

26 July 2017

8

Peter McLaughlin

1 reference

26 July 2017

4

Jorge Romaguera

1 reference

26 July 2017

1

Yasuhiro Oki

1 reference

26 July 2017

5

Felipe Samaniego

1 reference

26 July 2017

10

Anas Younes

1 reference

26 July 2017

9

Andre Goy

1 reference

PubMed ID

18085611

26 July 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

26 July 2017

1 reference

26 July 2017

112

1 reference

26 July 2017

4

1 reference

26 July 2017

831-836

1 reference

Reed-Sternberg cells and the TNF family of receptors/ligands

26 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23237

Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23237

7 January 2021

CD30 ligand is expressed on resting normal and malignant human B lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23237

7 January 2021

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23237

7 January 2021

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23237

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23237

7 January 2021

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23237

7 January 2021

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23237

7 January 2021

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23237

7 January 2021

Inhibitory effects of B cells on antitumor immunity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23237

7 January 2021

Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23237

7 January 2021

Identifiers

DOI

10.1002/CNCR.23237

1 reference

26 July 2017

1 reference

PubMed ID

18085611